MA35347B1 - Procedes therapeuiques - Google Patents

Procedes therapeuiques

Info

Publication number
MA35347B1
MA35347B1 MA36751A MA36751A MA35347B1 MA 35347 B1 MA35347 B1 MA 35347B1 MA 36751 A MA36751 A MA 36751A MA 36751 A MA36751 A MA 36751A MA 35347 B1 MA35347 B1 MA 35347B1
Authority
MA
Morocco
Prior art keywords
therapeutic methods
hepatitis
iib
administration
compound
Prior art date
Application number
MA36751A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35347(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA35347B1 publication Critical patent/MA35347B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé pour le traitement de l'hépatite c chez un humain le nécessitant comprenant l'administration d'un composé de formule (ii) ou (iib) décrites ici ou d'un de ses sels pharmaceutiquement acceptables en combinaison avec un ou plusieurs autres agents thérapeutiques contre l'hépatite c.
MA36751A 2011-08-17 2014-02-12 Procedes therapeuiques MA35347B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524429P 2011-08-17 2011-08-17
US201161526787P 2011-08-24 2011-08-24
PCT/US2012/051349 WO2013025992A1 (fr) 2011-08-17 2012-08-17 Procédés thérapeutiques

Publications (1)

Publication Number Publication Date
MA35347B1 true MA35347B1 (fr) 2014-08-01

Family

ID=47715500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36751A MA35347B1 (fr) 2011-08-17 2014-02-12 Procedes therapeuiques

Country Status (22)

Country Link
US (2) US9119868B2 (fr)
EP (1) EP2744342B1 (fr)
JP (2) JP6121419B2 (fr)
KR (2) KR20140093209A (fr)
CN (2) CN106109479A (fr)
AU (1) AU2012296446B2 (fr)
BR (1) BR112014003556A2 (fr)
CA (1) CA2843502C (fr)
CL (2) CL2014000394A1 (fr)
CO (1) CO6880064A2 (fr)
CR (1) CR20140075A (fr)
DO (1) DOP2014000030A (fr)
EA (2) EA024357B1 (fr)
ES (1) ES2735542T3 (fr)
IL (1) IL230484A (fr)
MA (1) MA35347B1 (fr)
MX (1) MX2014001833A (fr)
PE (1) PE20141391A1 (fr)
PH (1) PH12014500381A1 (fr)
SG (1) SG10201606646RA (fr)
WO (1) WO2013025992A1 (fr)
ZA (2) ZA201400435B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296446B2 (en) * 2011-08-17 2015-07-09 Glaxosmithkline Llc Therapeutic methods
ES2611731T3 (es) * 2011-08-19 2017-05-10 Glaxo Group Limited Compuestos de benzofurano para el tratamiento de infecciones por el virus de la hepatitis C
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
JP7086987B2 (ja) * 2017-03-21 2022-06-20 ザ スクリプス リサーチ インスティテュート 銅およびニッケル触媒による脱炭酸ホウ素化反応
CN114929715A (zh) * 2019-10-25 2022-08-19 住友制药株式会社 新型取代稠环型化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
WO2004041201A2 (fr) * 2002-11-01 2004-05-21 Viropharma Incorporated Composes de benzofurane, compositions et methodes utilisees pour le traitement et la prophylaxie des infections virales induites par l'hepatite c et des maladies associees
EP1686949A2 (fr) 2003-11-24 2006-08-09 Viropharma Incorporated Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
ES2377280T3 (es) * 2008-02-14 2012-03-26 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
WO2009137500A1 (fr) * 2008-05-05 2009-11-12 Wyeth Composés de benzofurane substitués en 6 pour traiter l’infection par le virus de l’hépatite c
WO2011050284A1 (fr) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Agents antiviraux de pyrazolylpyridine
AR080185A1 (es) * 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
TW201221131A (en) * 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
AU2012296446B2 (en) * 2011-08-17 2015-07-09 Glaxosmithkline Llc Therapeutic methods
WO2013025975A1 (fr) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Traitements combinés pour l'hépatite c
ES2611731T3 (es) * 2011-08-19 2017-05-10 Glaxo Group Limited Compuestos de benzofurano para el tratamiento de infecciones por el virus de la hepatitis C
MX2014002171A (es) * 2011-08-24 2014-04-25 Glaxosmithkline Llc Tratamientos de combinacion para hepatitis c.

Also Published As

Publication number Publication date
US20140212384A1 (en) 2014-07-31
KR20180129973A (ko) 2018-12-05
AU2012296446B2 (en) 2015-07-09
NZ619985A (en) 2016-06-24
ZA201502595B (en) 2017-01-25
PE20141391A1 (es) 2014-10-29
JP2017165732A (ja) 2017-09-21
EP2744342A1 (fr) 2014-06-25
EA024357B1 (ru) 2016-09-30
IL230484A (en) 2016-11-30
EP2744342A4 (fr) 2015-01-28
CN103929965B (zh) 2016-08-17
WO2013025992A1 (fr) 2013-02-21
AU2012296446A1 (en) 2014-02-13
CL2014000394A1 (es) 2014-08-01
US20150320777A1 (en) 2015-11-12
EA201690327A1 (ru) 2016-06-30
PH12014500381A1 (en) 2021-07-12
JP6121419B2 (ja) 2017-04-26
US9119868B2 (en) 2015-09-01
CA2843502C (fr) 2019-01-15
EP2744342B1 (fr) 2019-04-24
CA2843502A1 (fr) 2013-02-21
CN106109479A (zh) 2016-11-16
IL230484A0 (en) 2014-03-31
US10238678B2 (en) 2019-03-26
JP2014524446A (ja) 2014-09-22
CN103929965A (zh) 2014-07-16
ES2735542T3 (es) 2019-12-19
KR101975233B1 (ko) 2019-05-07
KR20140093209A (ko) 2014-07-25
CL2016000300A1 (es) 2016-09-02
EA201490199A1 (ru) 2015-01-30
BR112014003556A2 (pt) 2017-03-21
CR20140075A (es) 2014-03-24
EA201490199A8 (ru) 2015-12-30
ZA201400435B (en) 2015-09-30
SG10201606646RA (en) 2016-09-29
DOP2014000030A (es) 2014-06-30
CO6880064A2 (es) 2014-02-28
MX2014001833A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
MA35347B1 (fr) Procedes therapeuiques
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MA32903B1 (fr) Inhibiteurs de proteine-kinases
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA107112C2 (uk) Активатори розчинної гуанілатциклази
PH12014500386A1 (en) Combination treatment for hepatitis c
UA115320C2 (uk) Інгібітори кінази
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MY151295A (en) Pyrimidyl indoline compound
EA201391337A1 (ru) Ингибиторы hsp90
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MX342176B (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
EA201490573A1 (ru) Соединение бензотиазолона
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX342465B (es) Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
EA200870525A1 (ru) Фармацевтически приемлемые соли и полиморфные формы